Faculty of Pharmaceutical Sciences and Centre for Intellectual Property Rights, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Nat Rev Genet. 2012 May 18;13(6):441-8. doi: 10.1038/nrg3255.
Since the 1970s, patents on human genes and genetic diagnostic methods have been granted under the assumption that they stimulate the development of diagnostic methods and therapeutic products. However, the principles and practices of patenting vary between jurisdictions. Do patent holders, researchers, clinicians and patients really benefit from this heterogeneous patent system? We discuss the problems that result from the current system and suggest how they might be solved by altering the way in which patents are granted and/or licensed.
自 20 世纪 70 年代以来，授予了人类基因和基因诊断方法的专利，前提是它们可以促进诊断方法和治疗产品的开发。然而，专利授予的原则和实践在不同司法管辖区有所不同。专利持有人、研究人员、临床医生和患者是否真的从这个异质的专利系统中受益？我们讨论了当前系统所产生的问题，并提出了通过改变专利授予和/或许可的方式来解决这些问题的建议。
